| HOME >> MEDICINE >> TECHNOLOGY |
18.6%17.9%
20.6%Adjustments:Share-based compensation3,409
3,107
9.7%14,314
11,473
24.8%Amortization of acquired intangible assets408
484
(15.7%)1,983
1,549
28.0%Revaluation of contingent consideration(3,391)
-
NA(3,391)
-
NAImpairment charges for goodwill and intangible assets3,415
-
NA3,415
-
NANon-GAAP operating income27,398
23,803
15.1%105,740
96,832
9.2%Non-GAAP operating margin21.8%
21.9%21.2%
23.8%GAAP net income23,821
23,481
1.4%86,584
80,979
6.9%GAAP net margin19.0%
21.6%17.3%
19.9%Adjustments:Share-based compensation3,409
3,107
9.7%14,314
11,473
24.8%Amortization of acquired intangible assets408
484
(15.7%)1,983
1,549
28.0%Deferred tax impact related to acquired intangible assets(150)
(137)
9.5%(734)
(591)
24.2%Revaluation of contingent consideration(3,391)
-
NA(3,391)
-
NAImpairment charges for goodwill and intangible assets3,415
-
NA3,415
-
NANon-GAAP net income27,512
26,935
2.1%102,171
93,410
9.4%Non-GAAP net margin21.9%
24.8%20.4%
22.9%GAAP net income23,821
23,481
1.4%86,584
80,979
6.9%Add back:Depreciation and amortization11,468
9,361
22.5%41,672
33,997
22.6%Interest (income) expenses, net(1,487)
(1,819)
(18.3%)(6,010)
(5,266)
14.1%Income tax expenses (benefit)4,508
3,917
15.1%17,393
16,606
4.7%EBITDA38,310
34,940
9.6%139,639
126,316
10.5%Adjustments:Sh
'/>"/>
| SOURCE Wuxi PharmaTech Co. Ltd. Copyright©2012 PR Newswire. All rights reserved |